Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Australia
/
Pharmaceuticals & Biotech
/
Little Green Pharma
LGP
Little Green Pharma
Little Green Pharma set to double revenue amidst European expansion
BA
Babylonas
Not Invested
Community Contributor
Published
01 May 25
Updated
19 May 25
23
Set Fair Value
2
votes
1
Share
Babylonas
's Fair Value
AU$0.42
70.2% undervalued
intrinsic discount
19 May
AU$0.13
Loading
1Y
33.0%
7D
13.6%
Author's Valuation
AU$0.4
70.2% undervalued
intrinsic discount
Babylonas's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
Babylonas
's
Fair Value
AU$0.4
70.2% undervalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
-24m
52m
2017
2019
2021
2023
2025
2027
2029
2030
Revenue AU$51.9m
Earnings AU$7.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.45%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.48%
Calculation
AU$7.77m
Earnings '30
x
22.04x
PE Ratio '30
=
AU$171.21m
Market Cap '30
AU$171.21m
Market Cap '30
/
301.76m
No. shares '30
=
AU$0.57
Share Price '30
AU$0.57
Share Price '30
Discounted to 2025 @ 6.20% p.a.
=
AU$0.42
Fair Value '25
